Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes
Allergy · 2025
DOI: 10.1111/all.16296 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Allergy, 2025. Verfasst von Gádor Bogas und 12 weiteren Autor:innen. Beteiligte Einrichtung: Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain. Hauptthemen laut MEDLINE: Drug Hypersensitivity, Basophils, Basophil Degranulation Test, Taxoids. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 71 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Andalusian Regional Ministry Health, Andalusian Regional Goverment, Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO).
Abstract (Originalsprache)
Background
Delabelling pathways offer confirmatory diagnosis and can prevent unnecessary second‐line therapies or drug desensitization procedures after chemotherapeutic hypersensitivity reactions (CHT‐HSRs). However, these pathways rely on risky in vivo tests. Data on whether in vitro tests could be helpful are scarce. We assessed the role of basophil activation test (BAT) in the diagnosis of HSRs to platin salts (PSs) and taxanes (TXs) in a well‐defined population featuring varied endophenotypes and severities of HSRs.
Methods
We conducted a 3‐year‐long multicentric, prospective study with 121 suspected‐immediate CHT‐HSR patients. The allergy workup included clinical history (initial reaction based on Type I, cytokine release syndrome, and mixed phenotype's symptoms and if unable to fit in any of these, as “indeterminate”), skin testing (ST), and drug provocation testing (DPT), provided risk assessment was favorable. Final diagnosis classified patients as “hypersensitive,” “non‐hypersensitive,” or “inconclusive.” We performed BAT using CD63 and CD203c as activation markers in patients and controls. Patients underwent DPT regardless of BAT results to prevent bias.
Results
ST positivity significantly correlated with skin involvement, Type I phenotype, cancer recurrence, and lifetime exposures before reactions. DPTs were negative in all indeterminate phenotype patients ( p = .02) and those considered low‐risk, whereas they were negative in 62% moderate‐risk patients. 55% were confirmed as hypersensitive (mainly Type I reactions, p < .0001), 24% as non‐hypersensitive (mainly TXs and indeterminate phenotypes), and 21% as inconclusive. BAT showed 79% sensitivity in Type I IgE‐mediated reactions to PSs with a high correlation to ST.
Conclusions
BAT is a promising tool for delabelling and endotyping CHT‐HSRs, especially Type I reactions to PSs, possibly identifying patients at risk of positive DPT. ST seems useful in confirming CHT‐HSRs, especially PS‐induced reactions, and DPT remains the gold standard, being essential even in moderate‐risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Allergy Research Group, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina-IBIMA Plataforma BIONAND, Málaga, Spain.
- Allergy Unit, Hospital Regional Universitario de Málaga, Málaga, Spain.
- Drug Desensitization Centre, Catalan Institute of Oncology (Institut Català d'oncologia-ICO), Barcelona, Spain.
- Allergy Department, Hospital Universitari de Bellvitge, Barcelona, Spain.
- Allergy and Severe Asthma Service, St Bartholomew's Hospital, Barts Health NHS Trust, London, UK.
- Departamento de Medicina, Universidad de Málaga, Málaga, Spain.
ORCID-Profile: Gádor Bogas, Adriana Ariza, Paula Vázquez-Revuelta, Marina Labella, Ricardo Madrigal-Burgaleta, Rubén Fernández-Santamaría, Silvia Calvo-Serrano, Clara Lebrón-Martín, Cristobalina Mayorga, Inmaculada Doña, Maria J Torres
Förderung
- Andalusian Regional Ministry Health
- Andalusian Regional Goverment
- Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO)
- Instituto de Salud Carlos III (ISCIII) of the Ministry of Economy and Competitiveness (MINECO) and co-funded by Fondo Europeo de Desarrollo Regional-FEDER
- Ministerio de Economía y Competitividad
- Instituto de Salud Carlos III
Zitieren
APA
Bogas, G., Ariza, A., Vázquez-Revuelta, P., Labella, M., Madrigal-Burgaleta, R., Fernández-Santamaría, R., Calvo-Serrano, S., Villar-Chamorro, E., Martín-Clavo, S., Lebrón-Martín, C., Mayorga, C., Doña, I., & Torres, M. J. (2025). Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes. Allergy. https://doi.org/10.1111/all.16296
Vancouver
Bogas G, Ariza A, Vázquez-Revuelta P, Labella M, Madrigal-Burgaleta R, Fernández-Santamaría R, et al. Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes. Allergy. 2025. doi:10.1111/all.16296
BibTeX
@article{Bogas2025,
author = {Bogas, Gádor and Ariza, Adriana and Vázquez-Revuelta, Paula and Labella, Marina and Madrigal-Burgaleta, Ricardo and Fernández-Santamaría, Rubén and Calvo-Serrano, Silvia and Villar-Chamorro, Esther and Martín-Clavo, Susana and Lebrón-Martín, Clara and Mayorga, Cristobalina and Doña, Inmaculada and Torres, Maria J},
title = {Basophil activation test is a complementary tool in the diagnosis of immediate reactions to platinum salts and taxanes},
journal = {Allergy},
year = {2025},
doi = {10.1111/all.16296}
}
EUVIMED